Combinative treatment of β-elemene and cetuximab could induce ferroptosis of KRAS-mutant colorectal cancer cells (CRC) by iron-dependent ROS accumulation, GSH depletion, lipid peroxidation, upregulation of HO-1 and transferrin, and downregulation of negative regulatory proteins for ferroptosis (GPX4, SLC7A11, FTH1, glutaminase, and SLC40A1), thus inhibiting tumor growth and lymph node metastases in vivo (Chen et al., 2020b). The gene discussed is GPX4; the disease is neoplasm.